Endothelial Progenitor Cells in Coronary Artery Disease  by Fadini, Gian Paolo et al.
CORRESPONDENCE
Letters to the Editor
Endothelial Progenitor Cells
in Coronary Artery Disease
We have been prompted to write by the small study of Güven
et al. (1) showing increased endothelial progenitor cell (EPC)
colonies in patients with coronary artery disease (CAD). In
contrast, a wide literature demonstrates that the extent of the
EPC pool is an indicator of cardiovascular health, as EPCs
negatively correlate with severity of both peripheral and coro-
nary atherosclerosis (2,3).
The investigators attribute their paradoxical results to the longer
culture method they used to distinguish between true EPCs and
circulating angiogenic cells (CACs) in comparison with previous
studies. Even if we consider that earlier studies evaluated CACs
rather than true EPCs, the findings by Güven et al. (1) are
contrasting, because they report higher CACs in patients with
CAD. The researchers hypothesize that significantly ischemic
CAD triggers the mobilization of EPCs/CACs from bone mar-
row. However, patients with actual myocardial ischemia, for whom
increase in EPCs/CACs have been previously demonstrated, were
excluded from the study, and only patients with stable CAD were
enrolled. Moreover, whereas EPC colonies directly correlated with
maximum stenosis, they did not correlate with the number of
diseased vessels, which should be more informative on the extent
of myocardial ischemia.
We suggest that the use of intravascular ultrasound may provide
further information on coronary atherosclerosis and help explain
the paradoxical results when CAD is assessed angiographically.
Finally, should the data by Güven et al. (1) really reflect a
previously unknown regulation of EPCs in CAD, we would like to
offer a counter explanation: the increase in circulating cells with
high angiogenic potential dependent on CAD severity may be
causally related to plaque angiogenesis and growth (4) the Janus
face of EPCs in cardiovascular diseases.
*Gian Paolo Fadini, MD
Carlo Agostini, MD
Angelo Avogaro, MD, PhD
*Policlinico Universitario
Dipartimento di Medicina Clinica e Sperimentale
v. Giustiniani, 2
35100 Padova
Italy
E-mail: gianpaolofadini@hotmail.com
doi:10.1016/j.jacc.2007.01.058
REFERENCES
1. Güven H, Shepherd RM, Bach RG, Capoccia BJ, Link DC. The
number of endothelial progenitor cell colonies in the blood is increased
in patients with angiographically significant coronary artery disease.
J Am Coll Cardiol 2006;48:1579–87.
2. Fadini GP, Coracina A, Baesso I, et al. Peripheral blood
CD34KDR endothelial progenitor cells are determinants of sub-
clinical atherosclerosis in a middle-aged general population. Stroke
2006;37:2277–82.
3. Kunz GA, Liang G, Cuculoski F, et al. Circulating endothelial
progenitor cells predict coronary artery disease severity. Am Heart J
2006;152:190–5.
4. George J, Afek A, Abashidze A, et al. Transfer of endothelial progen-
itor and bone marrow cells influences atherosclerotic plaque size and
composition in apolipoprotein E knockout mice. Arterioscler Thromb
Vasc Biol 2005;25:2636–41.
Reply
We would like to thank Dr. Fadini and colleagues for their
comments regarding our study (1) recently published in JACC. Dr.
Fadini et al. point out that our data, which shows that the numbers
of endothelial progenitor cells (EPCs) and circulating angiogenic
cells (CACs) in the blood of patients referred for cardiac cathe-
terization are increased in those patients with angiographically
significant coronary artery disease (CAD), differs from the results
of some previously published studies. We agree. But as discussed in
our study and highlighted by Drs. Leor and Marber in an
accompanying editorial in JACC (2), it is critical when comparing
different studies that the type of circulating angiogenic cells be
precisely defined. Indeed, a recent study by Yoder et al. (3)
suggested that culture techniques commonly used to quantify
EPCs actually measure myeloid progenitor cells (3). In our study,
we used rigorous histological and flow cytometry techniques to
quantify EPCs and CACs (not simply a longer culture method, as
suggested by Dr. Fadini et al.). Furthermore, whereas we com-
pared these cell numbers to angiographically defined CAD among
patients across a wide spectrum of disease severity, many previous
studies identified atherosclerotic disease or its absence noninva-
sively, which may seriously limit sensitivity and specificity. We
agree that a more precise definition of atherosclerosis by, for
example, use of intravascular ultrasound, may add to our under-
standing of the relationship between the different EPC subsets and
CAD.
From our observations, we speculated that significant myocar-
dial ischemia may be a proximal determinant of EPC number in
the peripheral blood. Dr. Fadini et al. question this, but in support
of their opinion they wrongly state that patients with actual
myocardial ischemia were excluded from our study. Although
patients with acute myocardial infarction and unstable angina were
excluded from our investigation, the majority of our patients with
significant CAD were symptomatic (and anginal symptoms likely
underestimate the frequency of true myocardial ischemia). Impor-
tantly, we observed the highest numbers of circulating EPCs and
CACs in patients selected clinically to require revascularization. Of
relevance, previous studies have shown an increase in circulating
EPCs in patients with unstable angina (4) or acutely in response to
exercise-induced ischemia (5), observations that appear consistent
with the hypothesis that ischemia may be an important factor for
the number of circulating EPCs.
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